Oncotype DX肿瘤基因表达谱在II期结肠癌中的应用：预后评估、风险预测
Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.
作者信息
Webber Elizabeth M, Lin Jennifer S
机构信息
Kaiser Permanente Center for Health Research.
出版信息
PLoS Curr. 2010 Sep 2;2:RRN1177. doi: 10.1371/currents.RRN1177.
Abstract
Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.
摘要
II期结肠癌患者仅接受手术后的总体五年生存率平均为75%。然而，其中一些患者的预后较差，与III期疾病患者相似。拟使用的Oncotype DX检测旨在改善II期结肠癌复发的风险分层。
相似文献
1
Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.Oncotype DX肿瘤基因表达谱在II期结肠癌中的应用：预后评估、风险预测
PLoS Curr. 2010 Sep 2;2:RRN1177. doi: 10.1371/currents.RRN1177.
2
Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.用于预测II期和III期结肠癌患者复发风险的Oncotype DX（®）结肠癌检测：证据综述
Surg Oncol. 2015 Jun;24(2):61-6. doi: 10.1016/j.suronc.2015.02.001. Epub 2015 Feb 14.
3
Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.将肿瘤生物学转化为个性化治疗计划：Oncotype DX 结肠癌检测的分析性能特征。
BMC Cancer. 2010 Dec 23;10:691. doi: 10.1186/1471-2407-10-691.
4
BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.BreastPRS 是一种基因表达检测，可将中危 Oncotype DX 患者分为疾病复发的高风险或低风险。
Breast Cancer Res Treat. 2013 Jun;139(3):705-15. doi: 10.1007/s10549-013-2604-0. Epub 2013 Jun 18.
5
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.肿瘤分析测试指导早期乳腺癌辅助化疗决策：系统评价和经济分析。
Health Technol Assess. 2019 Jun;23(30):1-328. doi: 10.3310/hta23300.
6
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.Oncotype DX 对 ER 阳性、淋巴结阴性乳腺癌组织学相关性患者治疗决策的影响。
Breast J. 2013 May-Jun;19(3):269-75. doi: 10.1111/tbj.12099.
7
Oncotype DX in breast cancer patients: clinical experience, outcome and follow-up-a case-control study.乳腺癌患者的Oncotype DX检测：临床经验、结果及随访——一项病例对照研究
Arch Gynecol Obstet. 2018 Feb;297(2):443-447. doi: 10.1007/s00404-017-4618-z. Epub 2017 Dec 13.
8
Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.影响Oncotype DX在早期乳腺癌管理中应用的因素：单中心经验
Eur J Cancer. 2014 Oct;50(15):2544-9. doi: 10.1016/j.ejca.2014.07.010. Epub 2014 Aug 13.
9
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.从以色列管理的医疗机构的角度来看 21 基因乳腺癌风险检测的经济影响。
Value Health. 2010 Jun-Jul;13(4):381-7. doi: 10.1111/j.1524-4733.2010.00724.x. Epub 2010 Apr 15.
10
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.早期雌激素受体阳性/人表皮生长因子受体2阴性浸润性乳腺癌中部分容积校正后的最大标准化摄取值（SUVmax）与Oncotype DX复发评分之间的关联
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1574-84. doi: 10.1007/s00259-016-3418-1. Epub 2016 May 21.
引用本文的文献
1
Molecular pathological classification of colorectal cancer-an update.结直肠癌的分子病理分类——更新。
Virchows Arch. 2024 Feb;484(2):273-285. doi: 10.1007/s00428-024-03746-3. Epub 2024 Feb 6.
2
Predicting prognosis through the discovery of specific biomarkers according to colorectal cancer lymph node metastasis.根据结直肠癌淋巴结转移情况通过发现特定生物标志物预测预后。
Am J Cancer Res. 2023 Jul 15;13(7):3221-3233. eCollection 2023.
3
SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study.SAMHD1作为II期结直肠癌的预后和预测生物标志物：一项多中心队列研究。
Front Oncol. 2022 Aug 1;12:939982. doi: 10.3389/fonc.2022.939982. eCollection 2022.
4
Identification of a Novel Five-Gene Signature as a Prognostic and Diagnostic Biomarker in Colorectal Cancers.鉴定新型五基因标志物作为结直肠癌的预后和诊断生物标志物。
Int J Mol Sci. 2022 Jan 12;23(2):793. doi: 10.3390/ijms23020793.
5
A Novel TNM Classification for Colorectal Cancers based on the Metro-ticket Paradigm.基于地铁票范式的结直肠癌新型TNM分类
J Cancer. 2021 Apr 5;12(11):3299-3306. doi: 10.7150/jca.55097. eCollection 2021.
6
N-Glycomic Signature of Stage II Colorectal Cancer and Its Association With the Tumor Microenvironment.Ⅱ期结直肠癌的 N-糖基化特征及其与肿瘤微环境的关系。
Mol Cell Proteomics. 2021;20:100057. doi: 10.1074/mcp.RA120.002215. Epub 2021 Feb 11.
7
Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.Ⅱ期微卫星稳定结直肠肿瘤中的淋巴细胞浸润：一项回顾性预后生物标志物分析。
PLoS Med. 2020 Sep 24;17(9):e1003292. doi: 10.1371/journal.pmed.1003292. eCollection 2020 Sep.
8
MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer.基于福尔马林固定石蜡包埋组织的甲基化组学的 MethCORR 建模可用于结直肠癌的特征描述和预后判断。
Nat Commun. 2020 Apr 24;11(1):2025. doi: 10.1038/s41467-020-16000-6.
9
MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis.miR-486-5p 下调标志着结直肠癌发生的早期事件。
Dis Colon Rectum. 2018 Nov;61(11):1290-1296. doi: 10.1097/DCR.0000000000001192.
10
Gene Expression Detection Assay for Cancer Clinical Use.用于癌症临床应用的基因表达检测分析
J Cancer. 2018 Jun 5;9(13):2249-2265. doi: 10.7150/jca.24744. eCollection 2018.
本文引用的文献
1
Adjuvant therapy for completely resected stage II colon cancer.完全切除的II期结肠癌的辅助治疗。
Cochrane Database Syst Rev. 2008 Jul 16;2008(3):CD005390. doi: 10.1002/14651858.CD005390.pub2.
2
Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.使用761基因RT-PCR检测法发现结肠癌生物标志物。
BMC Genomics. 2007 Aug 15;8:279. doi: 10.1186/1471-2164-8-279.
Zotero 插件